Upadacitinib effectiveness and factors associated with minimal disease activity achievement in patients with psoriatic arthritis: preliminary data of a real-life multicenter study

Luchetti Gentiloni, Michele Maria; Paci, Valentino; Carletto, Antonio; Zabotti, Alen; Ramonda, Roberta; Chimenti, Maria Sole; Dagna, Lorenzo; Luciano, Nicoletta; Piccinelli, Anna; Giovannini, Ivan; Striani, Giovanni; Boffini, Nicola; Sandri, Gilda; Possemato, Niccolò; Pantano, Ilenia; Benfaremo, Devis; Salvarani, Carlo; Ciccia, Francesco; Selmi, Carlo; Moroncini, Gianluca

doi:10.1186/s13075-023-03182-9

Table 2 Clinical parameters, clinimetric test, and clinical response to the therapy in UPREAL-PsA study patients

From: Upadacitinib effectiveness and factors associated with minimal disease activity achievement in patients with psoriatic arthritis: preliminary data of a real-life multicenter study

	Baseline	w12	p^a	w24	p^b
Nr. of patients (%)	126 (100.0)	97 (77.0)	/	66 (52.4)	/
Disease-Clinimetric Indexes
Tender Joint Count, mean ± SD	9.36 ± 6.76	4.05 ± 4.70	< 0.001	3.59 ± 6.35	< 0.001
Swollen Joint Count, mean ± SD	3.02 ± 3.06	1.09 ± 2.53	< 0.001	0.86 ± 2.19	< 0.001
Leeds Enthesitis Index, mean ± SD	0.91 ± 1.41	0.33 ± 0.78	< 0.001	0.32 ± 0.77	0.0033
PASI, mean ± SD	1.34 ± 4.17	0.42 ± 1.06	0.0094	0.69 ± 3.15	0.0373
PtGA (scale 0–100) mean ± SD	71.99 ± 16.6	43.42 ± 20.9	< 0.001	36.06 ± 21.6	< 0.001
PGA (scale 0–100) mean ± SD	63.11 ± 16.2	31.92 ± 21.1	< 0.001	28.56 ± 23.8	< 0.001
VAS (scale 0–100) mean ± SD	71.21 ± 18.0	42.50 ± 24.7	< 0.001	33.11 ± 23.0	< 0.001
HAQ, mean ± SD	1.24 ± 0.90	0.66 ± 0.78	0.0709	0.44 ± 0.56	0.0075
C-Reactive Protein, mg/dl	0.99 ± 1.80	0.40 ± 0.75	< 0.001	0.35 ± 0.83	< 0.001
Composite Scores, global
MDA nr. (%)	0 (0.0)	29 (30.9)	/	31 (47.0)	/
VLDA nr. (%)	0 (0.0)	9 (9.6)	/	9 (13.6)	/
DAPSA, mean ± SD	27.65 ± 10.0	14.05 ± 9.48	< 0.001	11.77 ± 10.7	< 0.001
DAPSA minor improvement, nr. (%)	/	47 (48.5)	/	44 (66.7)	/
DAPSA moderate improvement, nr. (%)	/	23 (23.7)	/	26 (39.4)	/
DAPSA major improvement, nr. (%)	/	12 (12.4)	/	15 (22.7)	/
DAPSA LDA, nr. (%)	0 (0.0)	41 (42.3)	/	35 (53.0)	/
DAPSA remission status, nr. (%)	0 (0.0)	14 (14.4)	/	15 (22.7)	/
Composite Scores, axial
Nr. of patients with axial involvement (%)	54 (100)	38 (70.4)	/	23 (42.6)	/
ASDAS-CRP, mean ± SD	2.65 ± 0.69	1.71 ± 0.79	< 0.001	1.43 ± 0.78	0.0019
ASDAS-CRP CII, nr. (%)	/	18 (47.4)	/	15 (65.2)	/
ASDAS-CRP MI, nr. (%)	/	4 (10.5)	/	8 (34.8)	/
ASDAS-CRP LDA status, nr. (%)	0 (0.0)	12 (31.6)	/	9 (39.1)	/
ASDAS-CRP inactive disease status, nr. (%)	0 (0.0)	12 (31.6)	/	11 (47.8)	/

Variation of clinical parameters and clinimetric tests in response to the therapy in UPREAL-PsA (Upadacitinib therapy in the real-life in patients with psoriatic arthritis) study at week 12 (w12) and 24 (w24)
PASI Psoriasis Area Severity Index, PtGA Patient Global Assessment, PGA Physician Global Assessment, VAS pain Visual Analogue Scale for pain, HAQ Health Assessment Questionnaire, DAPSA Disease Activity in Psoriatic Arthritis, ASDAS-CRP Ankylosing Spondylitis Disease Activity Score/C-reactive protein, MDA or VLDA Minimal or Very Low Disease Activity, respectively, LDA low disease activity, CII clinically important improvement, MI major improvement. Statistical analysis conducted by “Stata” software (Paired Student’s t test test). P-value significant (in bold) if < 0.05; p^a between baseline and w12 and p^b between w12 vs w24

Back to article page

ISSN: 1478-6362

Contact us

General enquiries: journalsubmissions@springernature.com

Arthritis Research & Therapy

Contact us